viking therapeutics - Search News

News

Viking Therapeutics stock tumbles 37% today

Viking Therapeutics: What's Happening With VKTX Stock?

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk.

The Motley Fool on MSN · 1d

Why Viking Therapeutics Stock Crashed Today

Viking Therapeutics ( VKTX -43.72%) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what pharmaceutical analysts are calling "mixed results" for its new GLP-1 weight loss pill, VK2735.

Bloomberg · 1d

Viking Therapeutics Shorts Reap $514 Million as Stock Falls 40%

Viking Therapeutics Inc.’s worst stock drop in nine years has handed traders betting against the company a gain big enough to turn their money-losing year into a profitable one.

Viking, Therapeutics and Clinical Study

Yahoo Finance · 5h

Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s worst performers. Viking Therapeutics fell by 42.12 percent on Tuesday to close at $24.

Bloomberg · 1d

Viking Therapeutics Slumps as Weight-Loss Pill Study Underwhelms

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage study, marking another weaker-than-expected result for an oral alternative to popular weight-loss injections.

aktiencheck.de · 5h

Viking Therapeutics Shares Plunge on Clinical Trial Safety Concerns

Shares of Viking Therapeutics, Inc. (VKTX) experienced a dramatic sell-off, collapsing 42% following the release of new data for its weight-loss drug candidate, VK2735. The sharp decline reflects a significant shift in investor sentiment, moving from optimism to deep concern over the treatment's commercial viability.

13hon MSN

Here's Why Viking Therapeutics Bounced Back Today

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Viking Therapeutics: Panic Creates Opportunity

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

1don MSN

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Mizuho's Jared Holz joins 'Fast Money' to talk Viking Therapeutics' massive stock drop on new obesity pill data.

1don MSN

VKTX stock tumbles 29% today — Viking Therapeutics weight-loss trial results fuel massive investor sell-off and market jitters

Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...

Pharmabiz1d

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

1don MSN

This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Viking Therapeutics stock tumbles 37% today

Viking, Therapeutics and Clinical Study

Here's Why Viking Therapeutics Bounced Back Today

Viking Therapeutics: Panic Creates Opportunity

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

VKTX stock tumbles 29% today — Viking Therapeutics weight-loss trial results fuel massive investor sell-off and market jitters

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity

This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.

Related topics